Medical Marijuana, Inc. Major Investment AXIM Biotech Enters Clinical Study Agreement with University of British Columbia to Begin Clinical Trial On CBD Chewing Gum For Treatment of Drug-Related Psychosis

Medical Marijuana, Inc. Major Investment AXIM Biotech Enters Clinical Study Agreement with University of British Columbia to Begin Clinical Trial On CBD Chewing Gum For Treatment of Drug-Related Psychosis

SAN DIEGO, Aug. 3, 2017 — Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM) has entered into a Clinical...
AXIM Biotech Enters Services Agreement With Israel-Based CRO to Begin Clinical POC Study on CBD and Gabapentin Chewing Gum for Treatment of Restless Leg Syndrome

AXIM Biotech Enters Services Agreement With Israel-Based CRO to Begin Clinical POC Study on CBD and Gabapentin Chewing Gum for Treatment of Restless Leg Syndrome

AXIM Biotechnologies, Inc. (AXIM Biotech) AXIM, +2.42% a world leader in cannabinoid research and development, today announced that it has entered into a Services Agreement with an Israel-based contract research organization (CRO) to begin a clinical proof of concept...
Reuters Features Medical Marijuana, Inc.’s Major Investment Company AXIM Biotech In Article Citing Company’s Development Of Marijuana-Based Painkiller To Combat Opioid Crisis

Reuters Features Medical Marijuana, Inc.’s Major Investment Company AXIM Biotech In Article Citing Company’s Development Of Marijuana-Based Painkiller To Combat Opioid Crisis

NEW YORK, June 27, 2017 — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM), a world leader in...